These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

358 related articles for article (PubMed ID: 15912274)

  • 1. Positron emission tomography studies on binding of central nervous system drugs and P-glycoprotein function in the rodent brain.
    Elsinga PH; Hendrikse NH; Bart J; van Waarde A; Vaalburg W
    Mol Imaging Biol; 2005; 7(1):37-44. PubMed ID: 15912274
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PET Studies on P-glycoprotein function in the blood-brain barrier: how it affects uptake and binding of drugs within the CNS.
    Elsinga PH; Hendrikse NH; Bart J; Vaalburg W; van Waarde A
    Curr Pharm Des; 2004; 10(13):1493-503. PubMed ID: 15134571
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhanced cerebral uptake of receptor ligands by modulation of P-glycoprotein function in the blood-brain barrier.
    Doze P; Van Waarde A; Elsinga PH; Hendrikse NH; Vaalburg W
    Synapse; 2000 Apr; 36(1):66-74. PubMed ID: 10700027
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Uptake and binding of the serotonin 5-HT1A antagonist [18F]-MPPF in brain of rats: effects of the novel P-glycoprotein inhibitor tariquidar.
    la Fougère C; Böning G; Bartmann H; Wängler B; Nowak S; Just T; Wagner E; Winter P; Rominger A; Förster S; Gildehaus FJ; Rosa-Neto P; Minuzzi L; Bartenstein P; Potschka H; Cumming P
    Neuroimage; 2010 Jan; 49(2):1406-15. PubMed ID: 19796699
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New positron emission tomography tracer [(11)C]carvedilol reveals P-glycoprotein modulation kinetics.
    Bart J; Dijkers EC; Wegman TD; de Vries EG; van der Graaf WT; Groen HJ; Vaalburg W; Willemsen AT; Hendrikse NH
    Br J Pharmacol; 2005 Aug; 145(8):1045-51. PubMed ID: 15951832
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of a P-glycoprotein inhibitor, Cyclosporin A, on the disposition in rodent brain and blood of the 5-HT1A receptor radioligand, [11C](R)-(-)-RWAY.
    Liow JS; Lu S; McCarron JA; Hong J; Musachio JL; Pike VW; Innis RB; Zoghbi SS
    Synapse; 2007 Feb; 61(2):96-105. PubMed ID: 17117422
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclosporine, a P-glycoprotein modulator, increases [18F]MPPF uptake in rat brain and peripheral tissues: microPET and ex vivo studies.
    Laćan G; Plenevaux A; Rubins DJ; Way BM; Defraiteur C; Lemaire C; Aerts J; Luxen A; Cherry SR; Melega WP
    Eur J Nucl Med Mol Imaging; 2008 Dec; 35(12):2256-66. PubMed ID: 18604533
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Imaging the impact of cyclosporin A and dipyridamole on P-glycoprotein (ABCB1) function at the blood-brain barrier: A [(11)C]-N-desmethyl-loperamide PET study in nonhuman primates.
    Damont A; Goutal S; Auvity S; Valette H; Kuhnast B; Saba W; Tournier N
    Eur J Pharm Sci; 2016 Aug; 91():98-104. PubMed ID: 27283486
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Importance of P-gp PET Imaging in Pharmacology.
    Toyohara J
    Curr Pharm Des; 2016; 22(38):5830-5836. PubMed ID: 27494065
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discrepancies in the P-glycoprotein-mediated transport of (18)F-MPPF: a pharmacokinetic study in mice and non-human primates.
    Tournier N; Cisternino S; Peyronneau MA; Goutal S; Dolle F; Scherrmann JM; Bottlaender M; Saba W; Valette H
    Pharm Res; 2012 Sep; 29(9):2468-76. PubMed ID: 22644589
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modeling cyclosporine A inhibition of the distribution of a P-glycoprotein PET ligand, 11C-verapamil, into the maternal brain and fetal liver of the pregnant nonhuman primate: impact of tissue blood flow and site of inhibition.
    Ke AB; Eyal S; Chung FS; Link JM; Mankoff DA; Muzi M; Unadkat JD
    J Nucl Med; 2013 Mar; 54(3):437-46. PubMed ID: 23359659
    [TBL] [Abstract][Full Text] [Related]  

  • 12. (18)F-FCWAY, a serotonin 1A receptor radioligand, is a substrate for efflux transport at the human blood-brain barrier.
    Liow JS; Zoghbi SS; Hu S; Hall MD; Hines CS; Shetty HU; Araneta MD; Page EM; Pike VW; Kreisl WC; Herscovitch P; Gottesman MM; Theodore WH; Innis RB
    Neuroimage; 2016 Sep; 138():134-140. PubMed ID: 27211474
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of P-glycoprotein (abcb1a/b) modulation of [(18)F]fallypride in MicroPET imaging studies.
    Piel M; Schmitt U; Bausbacher N; Buchholz HG; Gründer G; Hiemke C; Rösch F
    Neuropharmacology; 2014 Sep; 84():152-8. PubMed ID: 23994301
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantitative assessment of P-glycoprotein function in the rat blood-brain barrier by distribution volume of [11C]verapamil measured with PET.
    Bart J; Willemsen AT; Groen HJ; van der Graaf WT; Wegman TD; Vaalburg W; de Vries EG; Hendrikse NH
    Neuroimage; 2003 Nov; 20(3):1775-82. PubMed ID: 14642487
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    García-Varela L; Rodríguez-Pérez M; Custodia A; Moraga-Amaro R; Colabufo NA; Aguiar P; Sobrino T; Dierckx RAJO; van Waarde A; Elsinga PH; Luurtsema G
    Mol Pharm; 2021 Aug; 18(8):3073-3085. PubMed ID: 34228458
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dose-response assessment of tariquidar and elacridar and regional quantification of P-glycoprotein inhibition at the rat blood-brain barrier using (R)-[(11)C]verapamil PET.
    Kuntner C; Bankstahl JP; Bankstahl M; Stanek J; Wanek T; Stundner G; Karch R; Brauner R; Meier M; Ding X; Müller M; Löscher W; Langer O
    Eur J Nucl Med Mol Imaging; 2010 May; 37(5):942-53. PubMed ID: 20016890
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Simultaneous PET imaging of P-glycoprotein inhibition in multiple tissues in the pregnant nonhuman primate.
    Eyal S; Chung FS; Muzi M; Link JM; Mankoff DA; Kaddoumi A; O'Sullivan F; Hebert MF; Unadkat JD
    J Nucl Med; 2009 May; 50(5):798-806. PubMed ID: 19403878
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modulation of P-glycoprotein at the Human Blood-Brain Barrier by Quinidine or Rifampin Treatment: A Positron Emission Tomography Imaging Study.
    Liu L; Collier AC; Link JM; Domino KB; Mankoff DA; Eary JF; Spiekerman CF; Hsiao P; Deo AK; Unadkat JD
    Drug Metab Dispos; 2015 Nov; 43(11):1795-804. PubMed ID: 26354948
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vivo evaluation of P-glycoprotein modulation of 8 PET radioligands used clinically.
    Ishiwata K; Kawamura K; Yanai K; Hendrikse NH
    J Nucl Med; 2007 Jan; 48(1):81-7. PubMed ID: 17204702
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased permeability-glycoprotein inhibition at the human blood-brain barrier can be safely achieved by performing PET during peak plasma concentrations of tariquidar.
    Kreisl WC; Bhatia R; Morse CL; Woock AE; Zoghbi SS; Shetty HU; Pike VW; Innis RB
    J Nucl Med; 2015 Jan; 56(1):82-7. PubMed ID: 25500831
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.